China SXT Pharmaceuticals - ADR Key Ratios
$2.23
As on 04-Sep-2026 16:00EDT
Market cap
$1 Mln
Revenue (TTM)
$-- Mln
P/E Ratio
--
P/B Ratio
0
Div. Yield
0 %
Key Ratios and Highlights
| Growth Score (%) | Quarterly | Annual (TTM) | |||
|---|---|---|---|---|---|
| Particulars | QoQ | YoY | 1-Year | 3-Years | 5-Years |
| Revenue | -- | 162.99 | -38.39 | -18.37 | -25.83 |
| EBIT | -- | 23.22 | -168.24 | -11.42 | -204.43 |
| Net Profit | -- | 113.09 | -87.83 | -1.54 | -176.26 |
| EPS | -- | 154.59 | -683.20 | 7.13 | -325.14 |
| Book Value | -- | -- | 702.32 | 14.21 | 118.08 |
| Key Ratios (%) | Average | Annual (TTM) | |||
|---|---|---|---|---|---|
| Particulars | 3-Years | 5-Years | Mar-26 | Mar-25 | Mar-24 |
| EBIT-Margin
| -316.35 | -286.45 | -664.06 | -152.53 | -132.45 |
| Net Margin
| -- | -- | -- | -- | -- |
| Return on equity
| -23.88 | -29.04 | -27.49 | -22.50 | -21.65 |
| Return on Capital
| -21.33 | -23.31 | -26.26 | -20.02 | -17.69 |
| Return on Assets
| -16.17 | -16.83 | -22.00 | -14.75 | -11.76 |
| Debt to Equity (x)
| -- | -- | 0.04 | 0.06 | 0.19 |
Profitability
ROCE
-26.26
--
Earning before interest and taxes / (Average net worth + Average total Debt) * 100
|
Company Name
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
China SXT Pharmaceuticals - ADR
|
-26.26
|
-20.02
|
-17.69
|
-26.02
|
-26.57
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
ROE
-27.49
--
Profit after tax / Average Net worth * 100
|
Company Name
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
China SXT Pharmaceuticals - ADR
|
-27.49
|
-22.50
|
-21.65
|
-38.15
|
-35.42
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
ROA
-22.00
--
Profit after tax / Average Total assets * 100
|
Company Name
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
China SXT Pharmaceuticals - ADR
|
-22.00
|
-14.75
|
-11.76
|
-18.81
|
-16.85
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
EBIT Margin
-664.06
--
Operating profit (EBIT) / Net Sales * 100
|
Company Name
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
China SXT Pharmaceuticals - ADR
|
-664.06
|
-152.53
|
-132.45
|
-276.82
|
-206.41
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Net Margin
-578.49
--
Net profit / Total Income (Net sales plus other income) * 100
|
Company Name
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
China SXT Pharmaceuticals - ADR
|
-578.49
|
-189.77
|
-160.67
|
-301.00
|
-220.43
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Revenue Growth
-0.38
--
Year on year growth in net sales
|
Company Name
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
China SXT Pharmaceuticals - ADR
|
-0.38
|
-0.10
|
-0.02
|
-0.24
|
-0.46
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
EBIT Growth
-168.24
--
Year on year growth in operating profit (EBIT)
|
Company Name
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
China SXT Pharmaceuticals - ADR
|
-168.24
|
-3.96
|
53.20
|
-1.62
|
-144.47
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Net Profit Growth
-87.83
--
Year on year growth in profit after tax
|
Company Name
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
China SXT Pharmaceuticals - ADR
|
-87.83
|
-6.62
|
47.79
|
-3.46
|
-108.72
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
EPS Growth
-6.83
--
Year on year growth in earnings per share
|
Company Name
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
China SXT Pharmaceuticals - ADR
|
-6.83
|
0.62
|
0.74
|
-3.87
|
-14.95
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Solvency
Debt to Equity
0.04
--
Total debt / Net worth
|
Company Name
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
China SXT Pharmaceuticals - ADR
|
0.04
|
0.06
|
0.19
|
0.26
|
0.65
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Short term debt to equity ratio
0.01
--
(Short term borrowings / Net worth)
|
Company Name
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
China SXT Pharmaceuticals - ADR
|
0.01
|
0.05
|
0.17
|
0.23
|
0.65
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Current Ratio
7.93
--
Current Assets / Current Liabilities and Provisions
|
Company Name
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
China SXT Pharmaceuticals - ADR
|
7.93
|
3.54
|
1.60
|
1.35
|
1.31
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Quick Ratio
7.25
--
(Current Assets - Inventory) / Current Liabilities and Provisions
|
Company Name
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
China SXT Pharmaceuticals - ADR
|
7.25
|
3.40
|
1.51
|
1.31
|
1.25
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Interest Coverage
-113.13
--
Earning before interest and taxes (EBIT) / Interest Expenses
|
Company Name
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
China SXT Pharmaceuticals - ADR
|
-113.13
|
-4.10
|
-4.69
|
-11.45
|
-146.38
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Operating Efficiency
Debtors to sales
301.35
--
Debtors outstanding / Net Sales * 100
|
Company Name
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
China SXT Pharmaceuticals - ADR
|
301.35
|
109.15
|
69.82
|
68.19
|
129.45
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Asset Turnover
0.04
--
Sales / Average Total Assets
|
Company Name
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
China SXT Pharmaceuticals - ADR
|
0.04
|
0.08
|
0.07
|
0.06
|
0.08
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Receivable days
873.85
--
Average Debtors / Sales * 365
|
Company Name
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
China SXT Pharmaceuticals - ADR
|
873.85
|
340.57
|
254.83
|
436.56
|
781.48
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Inventory Days
777.08
--
Average Inventory / Sales * 365
|
Company Name
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
China SXT Pharmaceuticals - ADR
|
777.08
|
217.77
|
178.17
|
188.97
|
260.63
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Payable days
340.04
--
Average Creditors / Cost of goods sold * 365
|
Company Name
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
China SXT Pharmaceuticals - ADR
|
340.04
|
324.14
|
353.07
|
337.98
|
397.34
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Cash Conversion Cycle
1,310.89
--
Receivable Days + Inventory Days - Payable Days
|
Company Name
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
China SXT Pharmaceuticals - ADR
|
1,310.89
|
234.20
|
79.93
|
287.55
|
644.76
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Valuation
Price / Earnings
-0.16
--
Current share price divided by earning per share in the last twelve months
|
Company Name
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
China SXT Pharmaceuticals - ADR
|
-0.16
|
-1.84
|
-0.47
|
-0.02
|
0.00
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Price / Book Value
0.03
--
Current share price divided by book value per share in the latest financial year
|
Company Name
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
China SXT Pharmaceuticals - ADR
|
0.03
|
0.39
|
0.10
|
0.01
|
0.00
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
EV/EBITDA
3.74
--
Enterprise Value (Current Market Capitalisation + Total Debt - Cash & Equivalents) / Earnings before interest, taxes, depreciation and taxes (EBITDA)
|
Company Name
|
Mar-26
|
Mar-25
|
Mar-24
|
Mar-23
|
Mar-22
|
|---|---|---|---|---|---|
|
China SXT Pharmaceuticals - ADR
|
3.74
|
4.34
|
3.39
|
2.59
|
0.94
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|